Form 13-F position report

SYNDAX PHARMACEUTICALS INC COM

Reported by D E Shaw & Co Inc

SNDX CUSIP 87164F105 Manager CIK 0001009207

Reported 644,542 shares, down 143,045 (18.2%) from the prior quarter.

Reported value -37.6%; share count -18.2% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 644,542 Quarter-end amount reported
Reported value $6,036,136 Fair value at quarter end
Consecutive quarters held 12 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2699000
2022-03-31 0
2022-09-30 3077000
2022-12-31 4083071
2023-03-31 2937095
2023-06-30 3621288
2023-09-30 2157265
2023-12-31 906864
2024-03-31 202871
2024-06-30 3010581
2024-09-30 6782892
2024-12-31 2434027
2025-03-31 9675506
2025-06-30 6036136
2025-09-30 16578645
2025-12-31 25623986
2026-03-31 37420290
2026-06-30 27105395
2026-09-30 9793691

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for SYNDAX PHARMACEUTICALS INC COM held by D E Shaw & Co Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 520,941 -719,013 (-58.0%) < 0.01% $9,793,691 2026-11-16
Q2 2026 Reduced 1,239,954 -361,942 (-22.6%) 0.01% $27,105,395 2026-08-14
Q1 2026 Added 1,601,896 +382,287 (31.3%) 0.02% $37,420,290 2026-05-15
Q4 2025 Added 1,219,609 +142,024 (13.2%) 0.01% $25,623,986 2026-02-17
Q3 2025 Added 1,077,585 +433,043 (67.2%) < 0.01% $16,578,645 2025-11-14
Q2 2025 Reduced 644,542 -143,045 (-18.2%) < 0.01% $6,036,136 2025-08-14
Q1 2025 Added 787,587 +603,470 (327.8%) < 0.01% $9,675,506 2025-05-15
Q4 2024 Reduced 184,117 -168,241 (-47.7%) < 0.01% $2,434,027 2025-02-14
Q3 2024 Added 352,358 +205,715 (140.3%) < 0.01% $6,782,892 2024-11-14
Q2 2024 Added 146,643 +138,119 (1620.4%) < 0.01% $3,010,581 2024-08-14
Q1 2024 Reduced 8,524 -33,441 (-79.7%) < 0.01% $202,871 2024-05-15
Q4 2023 Reduced 41,965 -106,607 (-71.8%) < 0.01% $906,864 2024-02-14
Q3 2023 Reduced 148,572 -24,447 (-14.1%) < 0.01% $2,157,265 2023-11-14
Q2 2023 Added 173,019 +33,952 (24.4%) < 0.01% $3,621,288 2023-08-14
Q1 2023 Reduced 139,067 -21,368 (-13.3%) < 0.01% $2,937,095 2023-05-15
Q4 2022 Added 160,435 +32,407 (25.3%) < 0.01% $4,083,071 2023-02-14
Q3 2022 New 128,028 +128,028 (0.0%) < 0.01% $3,077,000 2022-11-14
Q1 2022 Reduced 0 -123,303 (-100.0%) 0 $0 2022-05-16
Q4 2021 Reduced 123,303 -213,843 (-63.4%) < 0.01% $2,699,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

250 managers reported SYNDAX PHARMACEUTICALS INC COM for Q2 2025.

Managers reporting SYNDAX PHARMACEUTICALS INC COM in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 10,456,907 +1,914,656 < 0.01% $97,928,939 4 qtrs
Kynam Capital Management LP Unchanged 8,520,000 0 8.59% $79,789,800 15 qtrs
The Goldman Sachs Group Inc Added 5,797,195 +1,875,654 < 0.01% $54,290,731 31 qtrs
VANGUARD GROUP INC Added 5,033,934 +162,869 < 0.01% $47,142,793 37 qtrs
Eversept Partners LP Reduced 4,065,355 -146,915 3.5% $38,072,050 13 qtrs
Bank of America Corporation Added 3,838,872 +967,873 < 0.01% $35,951,035 36 qtrs
STATE STREET CORPORATION Reduced 3,442,752 -528,980 < 0.01% $32,241,373 37 qtrs
STEMPOINT CAPITAL LP Added 2,372,634 +774,040 7.13% $22,219,717 7 qtrs
FRANKLIN RESOURCES INC Added 2,359,677 +298,272 < 0.01% $22,098,378 7 qtrs
Point72 Asset Management L P Reduced 2,127,467 -1,881,233 0.04% $19,923,729 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
644,542
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.